CURATECH PHARMA PVT.LTD.
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based cGMP and ISO-oriented pharmaceutical manufacturer producing tablets, capsules, oral liquids, sachets and injectable products.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Curatech Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 35-KM, Multan Road, Lahore, Pakistan
- Website
- curatechpharma.com ↗
- Phone
- +92 42 35380374; +92 42 35380375
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Cipracin | Ciprofloxacin | 250 mg | Tablet | 10's | 046908 | PKR 240.05 | PKR 24.01/tablet | 6% below median |
| Cipracin | Ciprofloxacin | 500 mg | Tablet | 10's | 046997 | PKR 397.03 | PKR 39.70/tablet | 7% below median |
| Combozon 1g injectionRegistry verified | Cefoperazone as Sodium, Sulbactam as Sodium | — | — | — | 119268Official source ↗ | No indexed price | — | — |
| Combozon 2g injectionRegistry verified | Cefoperazone as Sodium, Sulbactam as Sodium | — | — | — | 119269Official source ↗ | No indexed price | — | — |
| Curafloxin | Levofloxacin | 250 mg | Tablet | 10's | 046906 | PKR 461.65 | PKR 46.17/tablet | Near median |
| Curafloxin | Levofloxacin | 500 mg | Tablet | 10's | 046907 | PKR 768.18 | PKR 76.82/tablet | Near median |
| Curalov | Carvedilol | 25 mg | Tablet | 10's | 069303 | PKR 322.72 | PKR 32.27/tablet | 24% below median |
| Curalov | Carvedilol | 6.25 mg | Tablet | 3x10's | 069304 | PKR 303.74 | PKR 10.12/tablet | 10% below median |
| Curaon | Ondansetron | 8 mg | Tablet | 10's | 101662 | PKR 1,290.59 | PKR 129.06/tablet | 23% below median |
| Curaqutol | Chloroquine | 250 mg | Tablet | 500's | 111910 | PKR 569.93 | PKR 1.14/tablet | 27% below median |
| Curaqutol-H | Hydroxychloroquine | 200 mg | Tablet | 50's | 111909 | PKR 594.11 | PKR 11.88/tablet | 18% below median |
| Curaqutol-H | Hydroxychloroquine | 200 mg | Tablet | 30's | 111909 | PKR 356.47 | PKR 11.88/tablet | 18% below median |
| Curaspan | Cefixime | 100 mg/5 mL | Suspension | 30ml | 055263 | PKR 314.25 | PKR 10.48/mL | Near median |
| Curaspan | Cefixime | 200 mg/5 mL | Suspension | 30ml | 055264 | PKR 384.55 | PKR 12.82/mL | Near median |
| Curaspan | Cefixime | 400 mg | Capsule | 1x5's | 055265 | PKR 563.10 | PKR 112.62/capsule | Near median |
| Curatam | Oseltamivir | 75 mg | Capsule | 10's | 111912 | PKR 990.19 | PKR 99.02/capsule | 18% below median |
| Curatral | Itraconazole | 100 mg | Capsule | 4's | 046912 | PKR 569.50 | PKR 142.38/capsule | Near median |
| Curaxone | Ceftriaxone | 1 g | Injection | 1's | 052994 | PKR 592.75 | PKR 592.75/vial/unit | Near median |
| Curaxone | Ceftriaxone | 500 mg | Injection | 1's | 052995 | PKR 313.93 | PKR 313.93/vial/unit | Near median |
| Curaxone | Ceftriaxone | 250 mg | Injection | 1's | 052996 | PKR 186.50 | PKR 186.50/vial/unit | Near median |
| Curazole | Omeprazole | 20 mg | Capsule | 2x7's | 046916 | PKR 265.90 | PKR 18.99/capsule | Near median |
| Ferifer | Iron polymaltose complex | 100 mg elemental iron | Tablet | 10's | 046902 | PKR 132.88 | PKR 13.29/tablet | Near median |
| Ferifer-F | Iron polymaltose complex + Folic acid | 100 mg elemental iron + 0.35 mg folic acid | Tablet | 10's | 046903 | PKR 132.88 | PKR 13.29/tablet | 6% below median |
| Ferifer-F | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Tablet | 30's | 046903 | PKR 366.39 | PKR 12.21/tablet | 8% below median |
| Fexozin | Fexofenadine | 120 mg | Tablet | 10's | 046904 | PKR 220.20 | PKR 22.02/tablet | 15% below median |
| Fexozin | Fexofenadine | 60 mg | Capsule | 10's | 060710 | PKR 104.42 | PKR 10.44/capsule | No comparator |
| Fexozin | Fexofenadine | 180 mg | Tablet | 10's | 062616 | PKR 284.76 | PKR 28.48/tablet | 15% below median |
| Flunazone | Fluconazole | 50 mg | Capsule | 7's | 046909 | PKR 830.97 | PKR 118.71/capsule | Near median |
| Flunazone | Fluconazole | 150 mg | Capsule | 1's | 046910 | PKR 254.84 | PKR 254.84/capsule | Near median |
| Lactaxin | Cephalexin | 250 mg | Capsule | 12's | 119014 | PKR 210.66 | PKR 17.56/capsule | 15% above median |
| Lactaxin | Cephalexin | 500 mg | Capsule | 12's | 119015 | PKR 413.06 | PKR 34.42/capsule | 12% above median |
| Melather | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 1x16's | 048068 | PKR 590.91 | PKR 36.93/tablet | 7% below median |
| Melather | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 12x8's | 048068 | PKR 3,261.07 | PKR 33.97/tablet | 15% below median |
| Melather DS | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 1x8's | 049467 | PKR 487.50 | PKR 60.94/tablet | Near median |
| Melather DS Plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 062613 | PKR 579.83 | PKR 96.64/tablet | 11% below median |
| Melather DS Plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 4's | 062613 | PKR 406.24 | PKR 101.56/tablet | 7% below median |
| Relovir DS | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 111911 | PKR 10,139.53 | PKR 84.50/tablet | 12% below median |
| Techmox | Moxifloxacin | 400 mg | Tablet | 5's | 101661 | PKR 712.82 | PKR 142.56/tablet | 23% below median |
| Tetraceph | Cefepime | 500 mg | Injection | 1's | 119270 | PKR 338.39 | PKR 338.39/vial/unit | No comparator |
| Tetraceph | Cefepime | 1 g | Injection | 1's | 119271 | PKR 566.03 | PKR 566.03/vial/unit | No comparator |
| Zicure | Azithromycin | 250 mg | Capsule | 6's | 046913 | PKR 282.53 | PKR 47.09/capsule | Near median |
| Zicure | Azithromycin | 250 mg | Capsule | 10's | 046913 | PKR 470.88 | PKR 47.09/capsule | Near median |
| Zicure | Azithromycin | 500 mg | Tablet | 6's | 106090 | PKR 388.48 | PKR 64.75/tablet | 24% below median |
| Zicure | Azithromycin | 250 mg | Tablet | 6's | 106091 | PKR 211.90 | PKR 35.32/tablet | 25% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.